Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Sage Therapeutics, Inc. (NASDAQ: SAGE).

Full DD Report for SAGE

You must become a subscriber to view this report.


Recent News from (NASDAQ: SAGE)

Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Sage Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that members of the Sage management team will participate in a fireside chat presentation at the Bank of...
Source: Business Wire
Date: May, 08 2018 06:30
Sage Therapeutics' (SAGE) CEO Jeff Jonas on Q1 2018 Results - Earnings Call Transcript
Sage Therapeutics (SAGE) Q1 2018 Results Earnings Conference Call May 3, 2018, 08:00 AM ET Executives Paul Cox - IR Jeff Jonas - CEO Steve Kanes - CMO Mike Cloonan - CBO Kimi Iguchi - CFO Jim Doherty - CRO Analysts Salveen Richter - Goldman Sachs Gary Nachman - BMO ...
Source: SeekingAlpha
Date: May, 03 2018 13:24
Sage Therapeutics 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Sage Therapeutics in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 03 2018 08:42
Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness
New Drug Application for intravenous (IV) formulation of brexanolone as a treatment for postpartum depression submitted to U.S. Food and Drug Administration Significant progress achieved in launch readiness preparations in anticipation of potential 1H 2019 brexanolone IV launch Br...
Source: Business Wire
Date: May, 03 2018 06:30
3 Things In Biotech, April 24: A Good, A Bad, And A Strong Maybe
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: April, 25 2018 08:00
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
Analysis focus: Roche Today we will discuss Roche (RHHBY), after the company announced data with its multiple sclerosis ((MS)) treatment Ocrevus from a long-term extension study. Ocrevus has seen strong uptake since its launch last year, and is expected to be a key value driver...
Source: SeekingAlpha
Date: April, 24 2018 08:00
Sage Therapeutics to Report First Quarter 2018 Financial Results on Thursday, May 3, 2018
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, May 3, 2018 at 8:00 A.M. ET to rep...
Source: Business Wire
Date: April, 24 2018 06:30
Biotech Analysis Central Pharma News: Synthetic Loses Designation, Sage Files NDA , Alnylam Gets Positive Opinion From EMA
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Synthetic Biologics Establishes Phase 3 Plan, Has Breakthrough Therapy Designation Status Pulled News: Recently, Synthetic Biologics ( SYN ) announ...
Source: SeekingAlpha
Date: April, 24 2018 03:11
Sage files U.S. marketing application for PPD med brexanolone; shares up 1% premarket
Sage Therapeutics (NASDAQ: SAGE ) submits its marketing application to the FDA seeking approval for intravenously administered SAGE-547 (brexanolone) for the treatment of postpartum depression (PPD), a Breakthrough Therapy indication. More news on: Sage Therapeutics, Healthcare stocks ne...
Source: SeekingAlpha
Date: April, 23 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-17175.01165.56175.09165.15580,998
2017-09-0785.8486.5987.4985.00291,958
2017-09-0685.9485.9886.67583.21284,391
2017-09-0586.8185.1687.600484.565289,315
2017-09-0182.3087.0087.7082.21382,324

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1321,75147,56545.7290Short
2018-08-1028,20148,69957.9088Short
2018-08-0926,09958,34944.7291Short
2018-08-0862,262111,72455.7284Short
2018-08-07130,433236,85155.0696Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SAGE.


About Sage Therapeutics, Inc. (NASDAQ: SAGE)

Logo for Sage Therapeutics, Inc. (NASDAQ: SAGE)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $7,936,535,692 - 05/11/2018
  • Issue and Outstanding: 46,515,858 - 04/26/2018

 


Recent Filings from (NASDAQ: SAGE)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 22 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: SAGE)

Daily Technical Chart for (NASDAQ: SAGE)


Stay tuned for daily updates and more on (NASDAQ: SAGE)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: SAGE)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SAGE is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of SAGE and does not buy, sell, or trade any shares of SAGE. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/